Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X
Scientific presentation

Myeloma Matters: Advancing Research and Therapy Development with Single-cell DNA + Protein Multi-Omics


Todd Druley, MD, PhD
Adam Sciambi, PhD

Description

Multiple myeloma is a complex form of plasma cell cancer that is currently untreatable. There are approximately 200,000 new diagnoses each year globally, with a 100% relapse rate and 54% five-year overall survival rate. In spite of significant advancements in treating blood-related cancers, these diseases continue to be a substantial cause of illness and death worldwide.

In this presentation, Dr. Todd Druley, MD, Ph.D., Chief Medical Officer of Mission Bio, and Co-Founder and Chief Technology Officer Dr. Adam Sciambi, Ph.D:

• Discuss the clinical impact and horizon of multiple myeloma therapies
• Present a novel approach to multiple myeloma therapeutic development by correlating SNVs, CNVs, and surface epitopes for clonal profiling
• Share clinical data generated by researchers from The Cancer Research Center of Toulouse IUCT-Oncopole and Genentech



VIEW


Scientific presentation
From Cells to Cures: Panel Discussion on Advancing Clonal Profiling in Leukemia & Myeloma With Single-Cell Multiomics
Hervé Avet-Loiseau, MD, PhD
Felipe Prósper, MD, PhD
Cedric Dos Santos, PhD
Todd Druley, MD, PhD
(2023)
Scientific presentation
Single Cell Multi-Omics & the MRD Horizon
Todd Druley, MD, PhD
Blake Alexander
(2023)
Scientific presentation
scTAM-seq: A Novel Method for Profiling DNA Methylation in Single Cells
Michael Scherer, PhD
Agostina Bianchi
(2023)
Scientific presentation
AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility
Aaron Llanso
AMP 2022 (2022)
REQUEST QUOTE